A multicenter phase 3 trial (NCT04669028) was started in August 2021 to investigate the safety and efficacy of NE3107 at 20 mg that was orally administered twice daily versus placebo in adult participants with mild-to-moderate AD
Wyniki te dotycz postaci farmaceutycznych tirzepatydu i pochodz z kontrolowanych bada klinicznych
Dado que estos frmacos ralentizan significativamente el vaciamiento gstrico, los pacientes frecuentemente experimentan efectos secundarios gastrointestinales, siendo el estreimiento uno de los ms comunes, reportado en hasta aproximadamente 25% de los usuarios con dosis para prdida de peso, segn las etiquetas de prescripcin de la FDA
*Correspondence: Pengfei Hu, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
NexLife operates in the compounded telehealth category, so it is most relevant to patients who have discussed compounded therapy with a clinician and understand the distinction